Compare Gilead Sciences, Inc. (GILD) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nebius Group NV — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Nebius Group NV trades at $174.1 (market cap $50.66B). The key difference: Gilead Sciences, Inc. is far larger — about 3.2× Nebius Group NV's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| GILD | NBIS | |
|---|---|---|
Market Cap | $163.51B | $50.66B |
Sector | Health | Technology |
52-Week High | $155.80 | $286.69 |
52-Week Low | $108.22 | $50.40 |
Enterprise Value | $178.05B | $50.85B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
NBIS trades at $171.75, down 11.46% over 24 hours amid broader tech sector volatility. The stock shows bearish technical signals with support at $174 and resistance at $197. Fundamentally, the company reported Q1 2026 EPS of -$0.23, beating expectations, while Q4 2025 missed. Revenue grew to $529.8M in 2025 with a strong net income margin of 93.09%. Recent news highlights a $1B compute deal with Reflection AI and positive analyst coverage despite recent price pressure.
Outlook remains positive with 87.5% analyst buy ratings and a $248 consensus price target, implying 44% upside. Key risks include competitive pressures from Meta's cloud capacity and high valuation multiples (P/E 77). The company's expansion into AI infrastructure and partnerships supports long-term growth, but investors should monitor execution on capacity build-out and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
